rogressive MS and relapsing MS. The MS Outcome Assessments Consortium (MSOAC) is bringing together industry, academia, patient representatives, regulatory and other government agencies to develop and obtain regulatory approval for clinician-reported outcome measures for use in progressive MS. The International Advisory Committee on Clinical Trials in MS has worked to refine the diagnostic criteria